PMID-35319491 – GH Replacement Safety in Cancer Survivors: Consensus Statement
Boguszewski CL et al. "Safety of growth hormone replacement in survivors of cancer and intracranial and sellar/parasellar tumours: a consensus statement," European Journal of Endocrinology, 2022;186(6):P35-P52. doi:10.1530/EJE-21-1186
Quick Reference
| Property | Value |
|---|---|
| PMID | 35319491 |
| DOI | 10.1530/EJE-21-1186 |
| Year | 2022 |
| Journal | European Journal of Endocrinology |
| Study Type | Consensus Statement / Narrative Review |
| Evidence Level | V |
| Sample | N/A (expert consensus based on systematic evidence review) |
| Peptide(s) Studied | GH-axis peptides (GH replacement as proxy) |
Key Findings
- Key conclusion: "No association between GH replacement and tumor recurrence" in cancer survivors with GH deficiency
- GH replacement can be safely initiated in cancer survivors after appropriate disease-free interval (typically 1-2 years post-remission)
- No evidence that GH replacement increases risk of secondary neoplasms
- Consensus recommends monitoring IGF-1 levels and maintaining within age-appropriate reference ranges
- Shared decision-making recommended with oncology team for active cancer patients
- Childhood cancer survivors with GH deficiency show no increased recurrence risk with GH therapy
Study Design
International expert consensus statement from the Growth Hormone Research Society, European Society of Endocrinology, and Pediatric Endocrine Society. Based on systematic review of available evidence including large registry studies, cohort analyses, and clinical experience. Developed through modified Delphi methodology.
Limitations
- Consensus statement, not original research — reflects expert opinion synthesizing available evidence
- Evidence base is largely observational; RCTs of GH in cancer survivors are ethically challenging
- Recommendations may not apply to supraphysiological GH/IGF-1 levels
- Does not directly address GH-secretagogue peptides, only exogenous GH replacement
Clinical Relevance
This consensus from three major endocrine societies provides the most authoritative safety guidance for GH-axis therapy in cancer survivors. The clear statement that GH replacement does not increase tumor recurrence is directly relevant for practitioners considering GH-secretagogue peptides (CJC-1295, Ipamorelin, Tesamorelin) in patients with cancer history. The key caveat: IGF-1 must be monitored and maintained within physiological range — supraphysiological levels are not addressed by this consensus.
Related
#research #narrative-review #evidence-level-V #cancer